

**COMPLETE LISTING OF THE CLAIMS**

This Listing of Claims will replace all prior versions and listings of claims in this application.

1. (Currently Amended) A monoclonal antibody produced by the hybridoma cell line deposited in the ATCC as patent deposit designation PTA-7448 designated as 7C8, or an antigen-binding fragment thereof, which binds specifically to an antigen present in human breast cancer, human lung cancer, or human bladder cancer.
2. (Cancelled)
3. (Currently amended) The monoclonal antibody or antigen-binding fragment thereof, according to claim 1, wherein the antigen-binding fragment is selected from the group consisting of Fab fragments, F(ab)<sub>2</sub> fragments, Fab' fragments, F(ab')<sub>2</sub> fragments, Fd fragments, Fd' fragments and Fv fragments.
4. (Currently amended) An anti-idiotypic antibody which mirrors the binding site of the antibody or antigen-binding fragment according to claim 1.
5. (Currently Amended) A hybridoma cell line which produces a monoclonal antibody, wherein said hybridoma cell line is deposited in the ATCC as patent deposit designation PTA-7448 is 7C8.

Claims 6-14 are cancelled.

15. (Withdrawn and Currently amended) A method of localizing cancer cells in a patient, comprising: (a) administering to the patient a detectably-labeled monoclonal antibody, or antigen-binding fragment thereof, according to claim 1; (b) allowing the detectably-labeled monoclonal antibody, or antigen-binding fragment thereof, to bind to the cancer cells within the patient; and (c) determining the location of the labeled monoclonal antibody or antigen-binding fragment thereof, within the patient.

Claims 16-21 are cancelled.

22. (Withdrawn and Currently amended) A method of imaging cancer in a patient, comprising administering to the patient the antibody or antigen-binding fragment thereof

according to claim 1, wherein the antibody or antigen-binding fragment thereof is detectably labeled with paramagnetic ions or with a radioisotope.

23. (Withdrawn and Currently amended) A pharmaceutical composition comprising the monoclonal antibody, or antigen-binding fragment thereof, according to claim 1, and a pharmaceutically acceptable carrier, excipient, or diluent.

24. (Currently amended) The monoclonal antibody or antigen-binding fragment thereof according to claim 1, labeled with a detectable moiety.

25. (Currently amended) The monoclonal antibody or antigen-binding fragment thereof according to claim 24, wherein the detectable moiety is selected from the group consisting of a fluorophore, a chromophore, a radionuclide, a chemiluminescent agent, a bioluminescent agent and an enzyme.

Claims 26-29 are cancelled.

30. (Currently amended) The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment is humanized or chimerized.

31. (Currently amended) A composition comprising the monoclonal antibody or ~~the~~ antigen-binding fragment thereof of claim 1.

32. (Currently amended) A kit comprising the monoclonal antibody or antigen-binding fragment thereof of claim 1.

Claims 33 and 34 are cancelled.